MedPath
HSA Approval

SUGAMMADEX KABI SOLUTION FOR INJECTION 100 MG/ML

SIN16988P

SUGAMMADEX KABI SOLUTION FOR INJECTION 100 MG/ML

SUGAMMADEX KABI SOLUTION FOR INJECTION 100 MG/ML

April 19, 2024

FRESENIUS KABI (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantFRESENIUS KABI (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

INTRAVENOUS

Medical Information

V03AB35

sugammadex

Manufacturer Information

FRESENIUS KABI (SINGAPORE) PTE LTD

Labesfal - Laboratórios Almiro, S.A.

Active Ingredients

Sugammadex Sodium eqv Sugammadex

100 mg/ml

Sugammadex

Documents

Package Inserts

Sugammadex Kabi Solution for Injection PI.pdf

Approved: April 19, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SUGAMMADEX KABI SOLUTION FOR INJECTION 100 MG/ML - HSA Approval | MedPath